Targeted Therapies and their Impact on Melanoma
Steven O’Day, MD
Video Categories: Targeted Therapies
Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.